Exploring the Ability of Meningococcal Vaccines to Elicit Mucosal Immunity: Insights from Humans and Mice

被引:4
作者
Currie, Elissa G. [1 ]
Gray-Owen, Scott D. [1 ]
机构
[1] Univ Toronto, Temerty Fac Med, Dept Mol Genet, Toronto, ON M5S 1A8, Canada
基金
英国科研创新办公室; 加拿大健康研究院;
关键词
Neisseria meningitidis; meningococcus; nasal infection; sepsis; vaccine; mucosal immunity; herd immunity; 4CMenB; humanized mouse model; NEISSERIA-MENINGITIDIS; SEROGROUP-B; FACTOR-H; CONJUGATE VACCINATION; BACTERICIDAL ANTIBODY; HERD-IMMUNITY; CARRIAGE; COMPLEMENT; PROTECTION; COLONIZATION;
D O I
10.3390/pathogens10070906
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Neisseria meningitidis causes a devastating invasive disease but is also a normal colonizer of the human nasopharynx. Due to the rapid progression of disease, the best tool to protect individuals against meningococcal infections is immunization. Clinical experience with polysaccharide conjugate vaccines has revealed that an ideal meningococcal vaccine must prevent both invasive disease and nasal colonization, which confers herd immunity. However, not all meningococcal vaccines are equal in their ability to prevent nasal colonization, for unknown reasons. Herein, we describe recent efforts to utilize humanized mouse models to understand the impact of different meningococcal vaccines on nasal colonization. These mice are susceptible to nasal colonization, and they become immune following live nasal infection or immunization with matched capsule-conjugate or protein-based vaccines, replicating findings from human work. We bring together insights regarding meningococcal colonization and immunity from clinical work with findings using humanized mouse models, providing new perspective into the different determinants of mucosal versus systemic immunity. Then, we use this as a framework to help focus future studies toward understanding key mechanistic aspects left unresolved, including the bacterial factors required for colonization and immune evasion, determinants of nasal mucosal protection, and characteristics of an ideal meningococcal vaccine.
引用
收藏
页数:11
相关论文
共 84 条
[1]   The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: Epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations [J].
Acevedo, Reinaldo ;
Bai, Xilian ;
Borrow, Ray ;
Caugant, Dominique A. ;
Carlos, Josefina ;
Ceyhan, Mehmet ;
Christensen, Hannah ;
Climent, Yanet ;
De Wals, Philippe ;
Dinleyici, Ener Cagri ;
Echaniz-Aviles, Gabriela ;
Hakawi, Ahmed ;
Kamiya, Hajime ;
Karachaliou, Andromachi ;
Lucidarme, Jay ;
Meiring, Susan ;
Mironov, Konstantin ;
Safadi, Marco A. P. ;
Shao, Zhujun ;
Smith, Vinny ;
Steffen, Robert ;
Stenmark, Bianca ;
Taha, Muhamed-Kheir ;
Trotter, Caroline ;
Vazquez, Julio A. ;
Zhu, Bingqing .
EXPERT REVIEW OF VACCINES, 2019, 18 (01) :15-30
[2]   A model of meningococcal bacteremia after respiratory superinfection in influenza A virus-infected mice [J].
Alonso, JM ;
Guiyoule, A ;
Zarantonelli, ML ;
Ramisse, F ;
Pires, R ;
Aude, A ;
Deghmane, AE ;
Huerre, M ;
van der Werf, S ;
Taha, MK .
FEMS MICROBIOLOGY LETTERS, 2003, 222 (01) :99-106
[3]   Carbohydrate vaccines: developing sweet solutions to sticky situations? [J].
Astronomo, Rena D. ;
Burton, Dennis R. .
NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (04) :308-324
[4]   Impact of meningococcal vaccination on carriage and disease transmission: A review of the literature [J].
Balmer, Paul ;
Burman, Cynthia ;
Serra, Lidia ;
York, Laura J. .
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (05) :1118-1130
[5]   A Meningococcal Outer Membrane Vesicle Vaccine with Overexpressed Mutant FHbp Elicits Higher Protective Antibody Responses in Infant Rhesus Macaques than a Licensed Serogroup B Vaccine [J].
Beernink, Peter T. ;
Vianzon, Vianca ;
Lewis, Lisa A. ;
Moe, Gregory R. ;
Granoff, Dan M. .
MBIO, 2019, 10 (03)
[6]   A Meningococcal Factor H Binding Protein Mutant That Eliminates Factor H Binding Enhances Protective Antibody Responses to Vaccination [J].
Beernink, Peter T. ;
Shaughnessy, Jutamas ;
Braga, Emily M. ;
Liu, Qin ;
Rice, Peter A. ;
Ram, Sanjay ;
Granoff, Dan M. .
JOURNAL OF IMMUNOLOGY, 2011, 186 (06) :3606-3614
[7]   Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB) [J].
Bettinger, Julie A. ;
Scheifele, David W. ;
Halperin, Scott A. ;
Vaudry, Wendy ;
Findlow, Jamie ;
Borrow, Ray ;
Medini, Duccio ;
Tsang, Raymond .
VACCINE, 2013, 32 (01) :124-130
[8]   A Decade of Herd Protection After Introduction of Meningococcal Serogroup C Conjugate Vaccination [J].
Bijlsma, Merijn W. ;
Brouwer, Matthijs C. ;
Spanjaard, Lodewijk ;
van de Beek, Diederik ;
van der Ende, Arie .
CLINICAL INFECTIOUS DISEASES, 2014, 59 (09) :1216-1221
[9]   Evaluation of strain coverage of the multicomponent meningococcal serogroup B vaccine (4CMenB) administered in infants according to different immunisation schedules [J].
Biolchi, Alessia ;
Tomei, Sara ;
Santini, Laura ;
Welsch, Jo Anne ;
Toneatto, Daniela ;
Gaitatzis, Nikolaos ;
Bai, Xilian ;
Borrow, Ray ;
Giuliani, Marzia Monica ;
Mori, Elena ;
Pizza, Mariagrazia .
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (03) :725-731
[10]   Neisseria meningitidis group B correlates of protection and assay standardization -: International meeting report Emory University, Atlanta, Georgia, United States, 16-17 march 2005 [J].
Borrow, R. ;
Carlone, G. M. ;
Rosenstein, N. ;
Plikaytis, B. ;
Blake, M. ;
Feavers, I. ;
Martin, D. ;
Zollinger, W. ;
Robbins, J. ;
Aaberge, I. ;
Granoff, D. M. ;
Miller, E. ;
van Alphen, L. ;
Poolman, J. ;
Rappuoli, R. ;
Danzig, L. ;
Hackell, J. ;
Danve, B. ;
Caulfield, M. ;
Lambert, S. ;
Stephens, D. .
VACCINE, 2006, 24 (24) :5093-5107